Therapies using anti-angiogenic peptide mimetics of thrombospondin-1

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 12, 2011, Pages 1369-1386

  Henkin, Jack ^a   Volpert, Olga V ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

angiogenesis; peptide mimetics; therapy; thrombosopndin 1

Indexed keywords

ANGIOGENESIS INHIBITOR; CD36 ANTIGEN; CD47 ANTIGEN; THROMBOSPONDIN 1;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; EYE DISEASE; GYNECOLOGIC DISEASE; HUMAN; INFLAMMATION; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVARY CANCER; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1;

EID: 83655191245     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.640319     Document Type: Review

References (186)

1. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 1990;87:6624-8
2. Kazerounian S, Yee KO, Lawler J. Thrombospondins in cancer. Cell Mol Life Sci 2008;65:700-12
3. Carlson CB, Lawler J, Mosher DF. Structures of thrombospondins. Cell Mol Life Sci 2008;283:672-86
4. Silverstein RL, Li W, Park YM, Rahaman SO. Mechanisms of cell signaling by the scavenger receptor CD36: implications in atherosclerosis and thrombosis. Trans Am Clin Climatol Assoc 2010;121:206-20
5. Simantov R, Silverstein RL. CD36: a critical anti-angiogenic receptor. Front Biosci 2003;8:s874-82 (Pubitemid 39144359)
6. Dawson DW, Pearce SF, Zhong R, et al. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997;138:707-17 (Pubitemid 27349849)
7. Jimenez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6:41-8 (Pubitemid 30048524)
8. Ridnour LA, Thomas DD, Donzelli S, et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal 2006;8:1329-37 (Pubitemid 44182431)
9. Hou J, Putkey JA, Hecht JT. Delta469 mutation in the type 3 repeat calcium binding domain of cartilage oligomeric matrix protein (COMP) disrupts calcium binding. Cell Calcium 2000;27:309-14
10. Wilson KE, Li Z, Kara M, et al. beta1 integrin- and proteoglycan-mediated stimulation of T lymphoma cell adhesion and mitogen-activated protein kinase signaling by thrombospondin-1 and thrombospondin-1 peptides. J Immunol 1999;163:3621-8 (Pubitemid 29450882)
11. Isenberg JS, Pappan LK, Romeo MJ, et al. Blockade of thrombospondin-1- CD47 interactions prevents necrosis of full thickness skin grafts. Ann Surg 2008;247:180-90
12. Bornstein P. Thrombospondins function as regulators of angiogenesis. J Cell Commun Signal 2009;3:189-200
13. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000;11:59-69 (Pubitemid 30169726)
14. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002;6:1-12 (Pubitemid 44133979)
15. Greenaway J, Lawler J, Moorehead R, et al. Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 2007;210:807-18 (Pubitemid 46185050)
16. Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol 2004;36:961-8 (Pubitemid 38528716)
17. Zhang X, Lawler J. Thrombospondin-based antiangiogenic therapy. Microvasc Res 2007;74:90-9 (Pubitemid 350064284)
18. Hoekstra R, de Vos FY, Eskens FA, et al. Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination. Eur J Cancer 2006;42:467-72 (Pubitemid 43227924)
19. Wang XQ, Lindberg FP, Frazier WA. Integrin-associated protein stimulates alpha2beta1-dependent chemotaxis via Gi-mediated inhibition of adenylate cyclase and extracellular-regulated kinases. J Cell Biol 1999;147:389-400
20. Carlson CB, Lawler J, Mosher DF. Thrombospondins: from structure to therapeutics: structures of thrombospondins. Cell Mol Life Sci 2008;65:672-86
21. Margosio B, Rusnati M, Bonezzi K, et al. Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. Int J Biochem Cell Biol 2008;40:700-9 (Pubitemid 351288589)
22. Tolsma SS, Volpert OV, Good DJ, et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993;122:497-511 (Pubitemid 23210475)
23. Miyata Y, Koga S, Takehara K, et al. Expression of thrombospondin-derived 4N1K peptide-containing proteins in renal cell carcinoma tissues is associated with a decrease in tumor growth and angiogenesis. Clin Cancer Res 2003;9:1734-40 (Pubitemid 36554598)
24. Kanda S, Shono T, Tomasini-Johansson B, et al. Role of thrombospondin-1-derived peptide, 4N1K, in FGF-2-induced angiogenesis. Exp Cell Res 1999;252:262-72 (Pubitemid 29530257)
25. Isenberg JS, Calzada MJ, Zhou L, et al. Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix Biol 2005;24:110-23 (Pubitemid 40693635)
26. Gupta K, Gupta P, Wild R, et al. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 1999;3:147-58 (Pubitemid 129644641)
27. Margosio B, Marchetti D, Vergani V, et al. Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. Blood 2003;102:4399-406 (Pubitemid 37494101)
28. Johansson U, Higginbottom K, Londei M. CD47 ligation induces a rapid caspase-independent apoptosis-like cell death in human monocytes and dendritic cells. Scand J Immunol 2004;59:40-9 (Pubitemid 38186838)
29. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006;1765:178-88
30. Armstrong LC, Bjorkblom B, Hankenson KD, et al. Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell 2002;13:1893-905 (Pubitemid 34651480)
31. Guo N, Krutzsch HC, Inman JK, Roberts DD. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 1997;57:1735-42 (Pubitemid 27199668)
32. Iruela-Arispe ML, Lombardo M, Krutzsch HC, et al. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 1999;100:1423-31 (Pubitemid 29451703)
33. Dawson DW, Volpert OV, Pearce SF, et al. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 1999;55:332-8 (Pubitemid 29076031)
34. Elzie CA, Murphy-Ullrich JE. The N-terminus of thrombospondin: the domain stands apart. Int J Biochem Cell Biol 2004;36:1090-101 (Pubitemid 38501561)
35. Gonias SL, Wu L, Salicioni AM. Low density lipoprotein receptor-related protein: Regulation of the plasma membrane proteome. Thromb Haemost 2004;91:1056-64 (Pubitemid 38821260)
36. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009;2:re3
37. Kuriki K, Hamajima N, Chiba H, et al. Increased risk of colorectal cancer due to interactions between meat consumption and the CD36 gene A52C polymorphism among Japanese. Nutr Cancer 2005;51:170-7 (Pubitemid 40734717)
38. Mirochnik Y, Kwiatek A, Volpert OV. Thrombospondin and apoptosis: Molecular mechanisms and use for design of complementation treatments. Curr Drug Targets 2008;9:851-62
39. Simantov R, Febbraio M, Silverstein RL. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 2005;24:27-34 (Pubitemid 40320896)
40. Asch AS, Liu I, Briccetti FM, et al. Analysis of CD36 binding domains: Ligand specificity controlled by dephosphorylation of an ectodomain. Science 1993;262:1436-40 (Pubitemid 24035064)
41. Klenotic PA, Huang P, Palomo J, et al. Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol 2010;176:2039-50
42. Daviet L, Malvoisin E, Wild TF, McGregor JL. Thrombospondin induces dimerization of membrane-bound, but not soluble CD36. Thromb Haemost 1997;78:897-901 (Pubitemid 27365591)
43. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8:349-57 (Pubitemid 34407029)
44. Aurora AB, Biyashev D, Mirochnik Y, et al. NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement. Blood 2010;116:475-84
45. Zaichuk TA, Shroff EH, Emmanuel R, et al. Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J Exp Med 2004;199:1513-22 (Pubitemid 38780406)
46. Ren B, Song K, Parangi S, et al. A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res 2009;69:3856-65
47. Rege TA, Stewart J Jr, Dranka B, et al. Thrombospondin-1-induced apoptosis of brain microvascular endothelial cells can be mediated by TNF-R1. J Cell Physiol 2009;218:94-103
48. Isenberg JS, Annis DS, Pendrak ML, et al. Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 2009;284(2):1116-25
49. McDonald JF, Dimitry JM, Frazier WA. An amyloid-like c-terminal domain of thrombospondin-1 displays CD47 agonist activity requiring both VVM motifs. Biochemistry 2003;284:10001-11 (Pubitemid 37012876)
50. Kvansakul M, Adams JC, Hohenester E. Structure of a thrombospondin C-terminal fragment reveals a novel calcium core in the type 3 repeats. EMBO J 2004;23:1223-33 (Pubitemid 38524995)
51. Floquet N, Dedieu S, Martiny L, et al. Human thrombospondin's (TSP-1) C-terminal domain opens to interact with the CD-47 receptor: a molecular modeling study. Arch Biochem Biophys 2008;478:103-9
52. Gao AG, Lindberg FP, Finn MB, et al. Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J Biol Chem 1996;271:21-4 (Pubitemid 26026555)
53. Gao AG, Frazier WA. Identification of a receptor candidate for the carboxyl-terminal cell binding domain of thrombospondins. J Biol Chem 1994;269:29650-7 (Pubitemid 24365121)
54. Miller TW, Isenberg JS, Roberts DD. Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase. Br J Pharmacol 2010;159:1542-7
55. Isenberg JS, Frazier WA, Krishna MC, et al. Enhancing cardiovascular dynamics by inhibition of thrombospondin- 1/CD47 signaling. Curr Drug Targets 2008;9:833-41
56. Maxhimer JB, Soto-Pantoja DR, Ridnour LA, et al. Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med 2009;1:3ra7
57. Ridnour LA, Thomas DD, Switzer C, et al. Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide 2008;19:73-6
58. Isenberg JS, Frazier WA, Roberts DD. Thrombospondin-1: a physiological regulator of nitric oxide signaling. Cell Mol Life Sci 2008;65:728-42
59. Kaur S, Martin-Manso G, Pendrak ML, et al. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem 2010;285:38923-32
60. Frazier EP, Isenberg JS, Shiva S, et al. Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47. Matrix Biol 2011;30:154-61
61. Bauer EM, Qin Y, Miller TW, et al. Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res 2010;88:471-81
62. Isenberg JS, Hyodo F, Pappan LK, et al. Blocking thrombospondin-1/ CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol 2007;27:2582-8 (Pubitemid 350158909)
63. Burnworth B, Arendt S, Muffler S, et al. The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1. Eur J Cell Biol 2007;86:763-80 (Pubitemid 350082194)
64. Bleuel K, Popp S, Fusenig NE, et al. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc Natl Acad Sci USA 1999;96:2065-70 (Pubitemid 29117868)
65. Fusenig NE, Boukamp P. Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol Carcinog 1998;23:144-58 (Pubitemid 28535818)
66. Liu BL, Cheng JX, Zhang W, et al. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro Oncol 2010;12:540-8
67. Guo W, Dong Z, He M, et al. Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma. J Biomed Biotechnol 2010;2010:721485
68. Oue N, Matsumura S, Nakayama H, et al. Reduced expression of the TSP1 gene and its association with promoter hypermethylation in gastric carcinoma. Oncology 2003;64:423-9 (Pubitemid 36682957)
69. Kang GH, Shim YH, Jung HY, et al. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 2001;61:2847-51 (Pubitemid 32691923)
70. Yang Q, Tian Y, Ostler KR, et al. Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer 2010;10:286
71. Hu CJ, Chen SD, Yang DI, et al. Promoter region methylation and reduced expression of thrombospondin-1 after oxygen-glucose deprivation in murine cerebral endothelial cells. J Cereb Blood Flow Metab 2006;26:151-1526
72. Michaud-Levesque J, Richard S. Thrombospondin-1 is a transcriptional repression target of PRMT6. J Biol Chem 2009;284:21338-46
73. Phelan MW, Forman LW, Perrine SP, Faller DV. Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells. J Lab Clin Med 1998;132:519-29 (Pubitemid 28564710)
74. Chen JK, Zhan YJ, Yang CS, Tzeng SF. Oxidative stress-induced attenuation of thrombospondin-1 expression in primary rat astrocytes. J Cell Biochem 2011;112:59-70
75. Raman P, Harry C, Weber M, et al. A novel transcriptional mechanism of cell type-specific regulation of vascular gene expression by glucose. Arterioscler Thromb Vasc Biol 2011;31:634-42
76. Garcia-Diaz DF, Arellano AV, Milagro FI, et al. Glucose and insulin modify thrombospondin 1 expression and secretion in primary adipocytes from diet-induced obese rats. J Physiol Biochem 2011;67:453-61
77. Zhou W, Dasgupta C, Negash S, Raj JU. Modulation of pulmonary vascular smooth muscle cell phenotype in hypoxia: role of cGMP-dependent protein kinase. Am J Physiol Lung Cell Mol Physiol 2007;292:L1459-66 (Pubitemid 47077362)
78. Sheibani N, Sorenson CM, Cornelius LA Frazier WA. Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia. Biochem Biophys Res Commun 2000;267:257-61 (Pubitemid 30072539)
79. Bongrazio M, Da Silva-Azevedo L, Bergmann EC, et al. Shear stress modulates the expression of thrombospondin-1 and CD36 in endothelial cells in vitro and during shear stress-induced angiogenesis in vivo. Int J Immunopathol Pharmacol 2006;19:35-48
80. Freyberg MA, Kaiser D, Graf R, et al. Proatherogenic flow conditions initiate endothelial apoptosis via thrombospondin-1 and the integrin-associated protein. Biochem Biophys Res Commun 2001;286:141-9 (Pubitemid 32917661)
81. Freyberg MA, Kaiser D, Graf R, et al. Integrin-associated protein and thrombospondin-1 as endothelial mechanosensitive death mediators. Biochem Biophys Res Commun 2000;271:584-8 (Pubitemid 30444671)
82. Lu P, Li L, Kuno K, et al. Protective roles of the fractalkine/CX3CL1- CX3CR1 interactions in alkali-induced corneal neovascularization through enhanced antiangiogenic factor expression. J Immunol 2008;180:4283-91
83. Yang G, Rosen DG, Liu G, et al. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 2010;16:3875-86
84. Wen XF, Yang G, Mao W, et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: Implications for HER2-targeted antibody therapy. Oncogene 2006;25:6986-96 (Pubitemid 44684839)
85. Culp WD, Tsagozis P, Burgio M, et al. Interference of macrophage migration inhibitory factor expression in a mouse melanoma inhibits tumor establishment by up-regulating thrombospondin-1. Mol Cancer Res 2007;5:1225-31
86. Morandi V, Cherradi SE, Lambert S, et al. Proinflammatory cytokines (interleukin-1beta and tumor necrosis factor-alpha) down regulate synthesis and secretion of thrombospondin by human endothelial cells. J Cell Physiol 1994;160:367-77
87. He J, Eastlack JP, Bazan HE. The induction of an angiogenic response in corneal myofibroblasts by platelet-activating factor (PAF). Curr Eye Res 2010;35:1063-71
88. Kuhn I, Bartholdi MF, Salamon H, et al. Identification of AKT-regulated genes in inducible MERAkt cells. Physiol Genomics 2001;7:105-14
89. Ghoneim C, Soula-Rothhut M, Blanchevoye C, et al. Activating transcription factor-1-mediated hepatocyte growth factor-induced downregulation of thrombospondin-1 expression leads to thyroid cancer cell invasion. J Biol Chem 2007;282:15490-7 (Pubitemid 47093298)
90. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 2003;100:12718-23 (Pubitemid 37339965)
91. Goel HL, Moro L, Murphy-Ullrich JE, et al. beta1 integrin cytoplasmic variants differentially regulate expression of the antiangiogenic extracellular matrix protein thrombospondin 1. Cancer Res 2009;69:5374-82
92. El Btaouri H, Morjani H, Greffe Y, et al. Role of JNK/ATF-2 pathway in inhibition of thrombospondin-1 (TSP-1) expression and apoptosis mediated by doxorubicin and camptothecin inFTC-133 cells. Biochim Biophys Acta 2011;1813:695-703
93. Ji W, Zhang W, Xiao W. E2F-1 directly regulates thrombospondin 1 expression. PLoS One 2010;15:e13442
94. Matsushita S, Ikeda R, Nishizawa Y, et al. The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells. Int J Oncol 2010;36:1193-200
95. Paasinen-Sohns A, Kaariainen E, Yin M, et al. Chaotic neovascularization induced by aggressive fibrosarcoma cells overexpressing S-adenosylmethionine decarboxylase. Int J Biochem Cell Biol 2011;43:441-54
96. Nelius T, Filleur S, Yemelyanov A, et al. Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer 2007;121:999-1008 (Pubitemid 47101635)
97. Yi J, Chang N, Liu X, et al. Reduced nuclear export of HuR mRNA by HuR is linked to the loss of HuR in replicative senescence. Nucleic Acids Res 2010;38:1547-58
98. Trapp V, Parmakhtiar B, Papazian V, et al. Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis 2010;13:305-15
99. Navarro FJ, Mirkin S, Archer DF. Effect of raloxifene, 17beta-estradiol, and progesterone on mRNA for vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 in Ishikawa cells. Fertil Steril 2003;79:1409-15 (Pubitemid 36687889)
100. Hyder SM, Liang Y, Wu J, Welbern V. Regulation of thrombospondin-1 by natural and synthetic progestins in human breast cancer cells. Endocr Relat Cancer 2009;16:809-17
101. McGray AJ, Gingerich T, Petrik JJ, Lamarre J. Regulation of thrombospondin-1 expression through AU-rich elements in the 3CUTR of the mRNA. Cell Mol Biol Lett 2011;16:55-68
102. Gubin MM, Calaluce R, Davis JW, et al. Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis. Cell Cycle 2010;9:3337-46
103. Almog N, Ma L, Raychowdhury R, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 2009;69:836-44
104. van Almen GC, Verhesen W, van Leeuwen RE, et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell 2011;10:769-79
105. Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38:1060-5 (Pubitemid 44325933)
106. Zhao HY, Ooyama A, Yamamoto M, et al. Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells. Cancer Lett 2008;270:156-63
107. Gutierrez LS, Suckow M, Lawler J, et al. Thrombospondin 1-a regulator of adenoma growth and carcinoma progression in the AMPMin/+ mouse model. Carcinogenesis 2003;24:199-207 (Pubitemid 36267087)
108. Maeda K, Nishiguchi Y, Yashiro M, et al. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma. Int J Mol Med 2000;5:373-8
109. Zhang J, Ito R, Oue N, et al. Expression of thrombospondin-1 is correlated with microvessel density in gastric carcinoma. Virchows Arch 2003;442:563-8 (Pubitemid 36819250)
110. Kiyono K, Suzuki HI, Morishita Y, et al. c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma. Cancer Sci 2009;100:1809-16
111. Yang QW, Liu S, Tian Y, et al. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res 2003;63:6299-310 (Pubitemid 37255177)
112. Willhauck MJ, Mirancea N, Vosseler S, et al. Reversion of tumor phenotype in surface transplants of skin scc cells by scaffold-induced stroma modulation. Carcinogenesis 2007;28:595-610 (Pubitemid 46523355)
113. Giri D, Ittmann M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum Pathol 1999;30:419-24 (Pubitemid 29177821)
114. Hsu SC, Volpert OV, Steck PA, et al. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res 1996;56:5684-91 (Pubitemid 26422173)
115. Mascaux C, Martin B, Paesmans M, et al. Expression of thrombospondin in non-small cell lung cancer. Anticancer Res 2002;22:1273-7 (Pubitemid 34836186)
116. Hu J, Bianchi F, Ferguson M, et al. Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer. Oncogene 2005;24:1212-19 (Pubitemid 40313922)
117. Rice A, Quinn CM. Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast. J Clin Pathol 2002;55:569-74
118. Alvarez AA, Axelrod JR, Whitaker RS, et al. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. Gynecol Oncol 2001;82:273-8 (Pubitemid 32730603)
119. Wu MP, Tzeng CC, Wu LW, et al. Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis. Cancer J 2004;10:27-32
120. Shariat SF, Youssef RF, Gupta A, et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 2010;183:1744-50
121. Ioachim E, Michael MC, Salmas M, et al. Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer 2006;6:140
122. Zubac DP, Bostad L, Kihl B, et al. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J Urol 2009;182:2144-9
123. Ordonez JL, Paraoan L, Hiscott P, et al. Differential expression of angioregulatory matricellular proteins in posterior uveal melanoma. Melanoma Res 2005;15:495-502 (Pubitemid 44124260)
124. Straume O, Akslen LA. Strong expression of ID1 protein is associated with decreased survival, increased expression ofephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. Br J Cancer 2005;93:933-8 (Pubitemid 41487020)
125. Velasco P, Lange-Asschenfeldt B. Dermatological aspects of angiogenesis. Br J Dermatol 2002;147:841-52 (Pubitemid 35365429)
126. Streit M, Velasco P, Brown LF, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999;155:441-52 (Pubitemid 29370394)
127. Tang D, Nagano H, Yamamoto H, et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin- 1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep 2006;15:525-32
128. Albo D, Shinohara T, Tuszynski GP. Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer. J Surg Res 2002;108:51-60 (Pubitemid 35373815)
129. Qian X, Rothman VL, Nicosia RF Tuszynski GP. Expression of thrombospondin-1 in human pancreatic adenocarcinomas: Role in matrix metalloproteinase-9 production. Pathol Oncol Res 2001;7:251-9 (Pubitemid 34174690)
130. Wang TN, Albo D, Tuszynski GP. Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production. Surgery 2002;132:220-5 (Pubitemid 35024765)
131. John AS, Hu X, Rothman VL, Tuszynski GP. Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: Exploring the functional significance in tumor cell invasion. Exp Mol Pathol 2009;87:184-8
132. Nathan FE, Hernandez E, Dunton CJ, et al. Plasma thrombospondin levels in patients with gynecologic malignancies. Cancer 1994;73:2853-8 (Pubitemid 24166276)
133. Campbell NE, Greenaway J, Henkin J, et al. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. Neoplasia 2010;12:275-83
134. Greenaway J, Henkin J, Lawler J, et al. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther 2009;8:64-74
135. Kawataki T, Naganuma H, Sasaki A, et al. Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma. Neuropathology 2000;20:161-9 (Pubitemid 32963612)
136. Li Q, Ahuja N, Burger PC, Issa JP. Methylation and silencing of the thrombospondin-1 promoter in human cancer. Oncogene 1999;18:3284-9 (Pubitemid 29286973)
137. Zhou L, Picard D, Ra YS, et al. Silencing of thrombospondin-1 is critical for myc-induced metastatic phenotypes in medulloblastoma. Cancer Res 2010;70:8199-210
138. Varani J, McKeever PE, Fligiel SE, Sitrin RG. Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions. Int J Cancer 1987;40:772-7 (Pubitemid 18003875)
139. Kawahara N, Ono M, Taguchi K, et al. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. Hepatology 1998;28:1512-17 (Pubitemid 28549120)
140. Hayashi K, Kurohiji T, Shirouzu K. Localization of thrombospondin in hepatocellular carcinoma. Hepatology 1997;25:569-74 (Pubitemid 27106435)
141. Maeno Y, Fujioka H, Hollingdale MR, et al. Ultrastructural localization of CD36 in human hepatic sinusoidal lining cells, hepatocytes, human hepatoma (HepG2-A16) cells, and C32 amelanotic melanoma cells. Exp Parasitol 1994;79:383-90 (Pubitemid 24359897)
142. Zak S, Treven J, Nash N Gutierrez LS. Lack of thrombospondin-1 increases angiogenesis in a model of chronic inflammatory bowel disease. Int J Colorectal Dis 2008;23:297-304
143. Punekar S, Zak S, Kalter VG, et al. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease. Pathobiology 2008;75:9-21 (Pubitemid 351365633)
144. Pfander D, Cramer T, Deuerling D, et al. Expression of thrombospondin-1 and its receptor CD36 in human osteoarthritic cartilage. Ann Rheum Dis 2000;59:448-54 (Pubitemid 30395602)
145. Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann NY Acad Sci 2002;955:89-100; discussion 118, 396-406
146. Tan XJ, Lang JH, Liu DY, et al. Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis. Fertil Steril 2002;78:148-53
147. Schellings MW, van Almen GC, Sage EH, Heymans S. Thrombospondins in the heart: Potential functions in cardiac remodeling. J Cell Commun Signal 2009;3:201-13
148. Isenberg JS, Qin Y, Maxhimer JB, et al. Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol 2009;28:110-19
149. Kang DH, Joly AH, Oh SW, et al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001;12:1434-47 (Pubitemid 32666326)
150. Hohenstein B, Daniel C, Hausknecht B, et al. Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy. Nephrol Dial Transplant 2008;23:3880-7
151. Hugo C, Kang DH, Johnson RJ. Sustained expression of thrombospondin-1 is associated with the development of glomerular and tubulointerstitial fibrosis in the remnant kidney model. Nephron 2002;90:460-70 (Pubitemid 34310111)
152. Garside SA, Henkin J, Morris KD, et al. A thrombospondin-mimetic peptide, ABT-898, suppresses angiogenesis and promotes follicular atresia in pre- and early-antral follicles in vivo. Endocrinology 2010;151:5905-15
153. Garside SA, Harlow CR, Hillier SG, et al. Thrombospondin-1 inhibits angiogenesis and promotes follicular atresia in a novel in vitro angiogenesis assay. Endocrinology 2010;151:1280-9
154. Thomas FH, Wilson H, Silvestri A, Fraser HM. Thrombospondin-1 expression is increased during follicular atresia in the primate ovary. Endocrinology 2008;149:185-92
155. Zamiri P, Masli S, Kitaichi N, et al. Thrombospondin plays a vital role in the immune privilege of the eye. Invest Ophthalmol Vis Sci 2005;46:908-19 (Pubitemid 41321027)
156. Masli S, Turpie B, Streilein JW. Thrombospondin orchestrates the tolerance-promoting properties of TGFbeta-treated antigen-presenting cells. Int Immunol 2006;18:689-99 (Pubitemid 43779059)
157. Turpie B, Yoshimura T, Gulati A, et al. Sjogren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice. Am J Pathol 2009;175:1136-47
158. He S, Incardona F, Jin M, et al. Thrombospondin-1 expression in RPE and choroidal neovascular membranes. Yan Ke Xue Bao 2006;22:265-74
159. Uno K, Bhutto IA, McLeod DS, et al. Impaired expression of thrombospondin-1 in eyes with age related macular degeneration. Br J Ophthalmol 2006;90:48-54 (Pubitemid 43029896)
160. Wang S, Gottlieb JL, Sorenson CM, Sheibani N. Modulation of thrombospondin 1 and pigment epithelium-derived factor levels in vitreous fluid of patients with diabetes. Arch Ophthalmol 2009;127:507-13
161. Scheef EA, Sorenson CM, Sheibani N. Attenuation of proliferation and migration of retinal pericytes in the absence of thrombospondin-1. Am J Physiol Cell Physiol 2009;296:C724-34
162. Mousa SA, Lorelli W, Campochiaro PA. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. J Cell Biochem 1999;74:135-43 (Pubitemid 29270036)
163. Iruela-Arispe ML, Luque A, Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 2004;36:1070-8 (Pubitemid 38501558)
164. Johnson ES, Seely JH, White WF, DeSombre ER. Endocrine-dependent rat mammary tumor regression: use of a gonadotropin releasing hormone analog. Science 1976;194:329-30
165. Haviv F, Bradley MF, Kalvin DM, et al. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. J Med Chem 2005;48:2838-46 (Pubitemid 40548098)
166. Reiher FK, Volpert OV, Jimenez B, et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 2002;98:682-9 (Pubitemid 34225618)
167. Rusk A, McKeegan E, Haviv F, et al. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 2006;12:7444-55
168. Shaked Y, Bertolini F, Man S, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005;7:101-11 (Pubitemid 40126386)
169. Quesada AJ, Nelius T, Yap R, et al. In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ 2005;12:649-58 (Pubitemid 40767167)
170. Yap R, Veliceasa D, Emmenegger U, et al. Metronomic low-dose chemotherapy boosts cd95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 2005;11:6678-85 (Pubitemid 41339009)
171. Isenberg JS, Yu C, Roberts DD. Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol 2008;75:875-82
172. Rath GM, Schneider C, Dedieu S, et al. Thrombospondin-1 C-terminal-derived peptide protects thyroid cells from ceramide-induced apoptosis through the adenylyl cyclase pathway. Int J Biochem Cell Biol 2006;38:2219-28 (Pubitemid 44419501)
173. Anderson JC, Grammer JR, Wang W, et al. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis. Cancer Biol Ther 2007;6:454-62 (Pubitemid 47328316)
174. Nabors LB, Fiveash JB, Markert JM, et al. A Phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol 2010;67:313-19
175. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96 (Pubitemid 40349501)
176. Hoekstra R, de Vos FY, Eskens FA, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 2005;23:5188-97 (Pubitemid 46224028)
177. Gietema JA, Hoekstra R, de Vos FY, et al. A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 2006;17:1320-7 (Pubitemid 44288225)
178. Gordon MS, Mendelson D, Carr R, et al. A Phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer 2008;113:3420-9
179. Ebbinghaus S, Hussain M, Tannir N, et al. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 2007;15:6689-95 (Pubitemid 350206805)
180. Markovic SN, Suman VJ, Rao RA, et al. A Phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 2007;30:303-9 (Pubitemid 46884153)
181. Baker LH, Rowinsky EK, Mendelson D, et al. Randomized, Phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 2008;26:5583-8
182. Yang Q, Tian Y, Liu S, et al. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 2007;67:1716-24 (Pubitemid 46383398)
183. Fukumura D, Jain RK. Tumor microvasculature and microenvironment: Targets for anti-angiogenesis andnormalization. Microvasc Res 2007;74:72-84 (Pubitemid 350051025)
184. Hasina R, Martin LE, Kasza K, et al. Abt-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis. Cancer Prev Res (Phila) 2009;2:385-93
185. Thaunat O, Louedec L, Graff-Dubois S, et al. Antiangiogenic treatment prevents adventitial constrictive remodeling in graft arteriosclerosis. Transplantation 2008;85:281-9 (Pubitemid 351156859)
186. Campbell N, Greenaway J, Henkin J Petrik J. ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer. Mol Cancer Ther 2011;10:1876-85